This analysis was based on a retrospective analysis of a multicenter, randomized, placebo-controlled study of zoledronic acid in 46 RCC patients with bone metastases.

• 该分析是基于一个46个有骨转移肾癌病人的多中心，随机，安慰剂对照，回顾性研究。